Summit Therapeutics Ivonescimab In Combination with Chemotherapy Approved In China By NMPA For 2L+ EGFRm NSCLC Based On HARMONi-A Clinical Trial; Clinically Meaningful Efficacy Observed In Overall Survival Towards Ivonescimab Plus Chemotherapy; Shares Currently Halted
Portfolio Pulse from Benzinga Newsdesk
Summit Therapeutics Inc. (NASDAQ:SMMT) announced that its partner, Akeso Inc., received marketing authorization in China for ivonescimab in combination with chemotherapy for 2L+ EGFRm NSCLC based on the HARMONi-A clinical trial. The trial showed significant improvements in progression-free survival and overall response rate. Shares of Summit Therapeutics are currently halted.
June 01, 2024 | 2:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Summit Therapeutics' partner Akeso received approval in China for ivonescimab in combination with chemotherapy for 2L+ EGFRm NSCLC. The HARMONi-A trial showed significant improvements in progression-free survival and overall response rate. Shares are currently halted.
The approval of ivonescimab in China is a significant milestone for Summit Therapeutics, indicating potential revenue growth and market expansion. The positive clinical trial results further support the efficacy of the drug, likely boosting investor confidence. The halt in shares suggests a pending significant announcement or reaction in the market.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100